TAK-079
E852350
TAK-079 is an investigational human monoclonal antibody designed to deplete CD38-expressing cells, primarily being developed for the treatment of multiple myeloma and certain autoimmune diseases.
Statements (29)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medicinal product
ⓘ
investigational drug ⓘ monoclonal antibody ⓘ |
| actsOn |
CD38-positive immune cells
ⓘ
CD38-positive malignant plasma cells ⓘ |
| bindsTo | CD38-expressing cells ⓘ |
| developedBy | Takeda Pharmaceutical Company Limited NERFINISHED ⓘ |
| developedForIndication |
autoantibody-mediated diseases
ⓘ
autoimmune diseases ⓘ multiple myeloma ⓘ systemic lupus erythematosus ⓘ |
| hasDevelopmentStatus | investigational ⓘ |
| hasIntendedEffect | depletion of CD38-expressing cells ⓘ |
| hasMechanismOfAction |
antibody-dependent cellular cytotoxicity
ⓘ
apoptosis induction in CD38-positive cells ⓘ complement-dependent cytotoxicity ⓘ |
| hasMoleculeType | human monoclonal antibody ⓘ |
| hasRouteOfAdministration | subcutaneous administration ⓘ |
| hasSpeciesOrigin | human ⓘ |
| hasTarget | CD38 NERFINISHED ⓘ |
| hasTherapeuticArea |
hematology
ⓘ
immunology ⓘ oncology ⓘ |
| isAdministeredAs | parenteral formulation ⓘ |
| isComparedWith | other anti-CD38 antibodies ⓘ |
| isDesignedTo |
modulate immune system activity
ⓘ
reduce pathogenic autoantibodies ⓘ |
| targetsCellType |
CD38-positive lymphocytes
ⓘ
plasma cells ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.